None listed
Conditions
Brief summary
This pilot study aims to gain preliminary information on the utility of C-MET and FLT PET-CT imaging for distinguishing ‘pseudoprogression’ from ‘true’ progression in patients receiving chemoradiotherapy for high grade glioma. C-MET and FLT PET-CT scans will be performed at the same time as their routine mid-treatment MRI (after 2-3 cycles of chemotherapy. Patients will be followed to record radiological and clinical responses to chemotherapy. Patients will also be followed up for survival. This data will be used to obtain preliminary information of the prognostic significance of C-MET and FLT PET-CT imaging in glioma
Interventions
11C-Methionine (C-MET) and 18F-Fluorothymidine (FLT) imaging will be performed on all consenting eligible patients receiving adjuvant temozolomide containing chemotherapy, at the same time as their routine mid-treatment Magnetic Resonance Imaging (MRI) scan. Current routine care at our institution involves an MRI following 3 cycles of adjuvant temozolamide chemotherapy. Several clinical trials are however commencing which require an MRI after 2 cycles of temozolamide chemotherapy and thus the pr
11C-Methionine (C-MET) and 18F-Fluorothymidine (FLT) imaging will be performed on all consenting eligible patients receiving adjuvant temozolomide containing chemotherapy, at the same time as their routine mid-treatment Magnetic Resonance Imaging (MRI) scan. Current routine care at our institution involves an MRI following 3 cycles of adjuvant temozolamide chemotherapy. Several clinical trials are however commencing which require an MRI after 2 cycles of temozolamide chemotherapy and thus the protocol will allow the C-MET and FLT PET-CT scans to coincide with the patient’s planned MRI scan which will be performed either after cycle 2 or 3 of adjuvant chemotherapy. A cycle is defined as temozolomide administered days 1-5 every 28 days. Patients who are not treated in this way will not be eligible. Information on the number of cycles will be obtained from the treating medical oncologist; start dates of each cycle will be recorded. For the C-MET PET-CT scan intravenous dose administered will be 300 MBq/m2 according to patient body surface area (BSA). For the FLT PET-CT scan intravenous dose administered will be 100 MBq/m2 according to patient BSA
Sponsors
Sir Charles Gairdner Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Histologically confirmed malignant glioma (grades III-IV), Received surgical biopsy or debulking, radiotherapy, and commenced adjuvant chemotherapy with a temozolomide-containing chemotherapy regimen, Planned for routine MRI following 2 or 3 cycles of adjuvant chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, able to undertake MRI and PET-CT imaging, written informed consent.
Exclusion criteria
Pregnancy, age less than 18 years, Medical contraindication to MRI or PET-CT imaging, Cognitive impairment considered to impair the ability to give written informed consent in the opinion of the treating clinician
Outcome results
None listed